Given the prevalent role of PAX5 in epithelialization and EMT-MET processes in breast cancer cells [75,101], it has been suggested that miR-210 likely targets PAX5 during tumor neoplasm and hypoxia to produce a robust, comprehensive shift from epithelial to mesenchymal phenotypic features to evade hypoxic insult [164]. This evidence concerns the gene PAX5 and breast cancer.